-
Something wrong with this record ?
Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs
M. Hruby, K. Agrawal, O. Policianova, J. Brus, J. Skopal, P. Svec, M. Otmar, P. Dzubak, P. Stepanek, M. Hajduch
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
27003313
DOI
10.5507/bp.2016.013
Knihovny.cz E-resources
- MeSH
- Azacitidine administration & dosage analogs & derivatives pharmacology MeSH
- Infusion Pumps, Implantable MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Magnetic Resonance Spectroscopy MeSH
- Microspheres MeSH
- Polymers chemistry MeSH
- Antimetabolites, Antineoplastic administration & dosage pharmacology MeSH
- Absorbable Implants MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs is confounded by their hydrolytic lability which decreases plasma circulation time. Here, we describe a new biodegradable, polyanhydride formulation for drug delivery that circumvents this drawback. METHODS: Injectable/implantable polymeric microbeads containing dispersed microcrystals of hydrophilic AZA or DAC packed in a dry environment are protected from hydrolysis, until the hydrolytic zone reaches the core. Diclofenac is embedded into the formulation to decrease any local inflammation. The efficacy of the formulations was confirmed by monitoring the induced demethylation, and cytostatic/cytotoxic effects of continuous drug release from the time-course dissolution of the microbeads, using an in vitro developed cell based reporter system. RESULTS: Poly(sebaccic acid-co-1,4-cyclohexanedicarboxylic acid) containing 30 wt. % drug showed zero-order release (R(2) = 0.984 for linear regression), and release rate of 10.0 %/h within the first 5 h, and subsequent slower release of the remaining drug, thus maintaining the level of drugs in the outer environment considerably longer than the typical plasma half-life of free azanucleosides. At lower concentrations, the differences between powder drug formulations and microbeads were very low or negligible, however, at higher concentrations, we discovered equivalent or increasing effects of the drugs loaded in microbeads. CONCLUSIONS: The study provides evidence that microbead formulations of the hydrolytically labile azanucleoside drugs could prevent their chemical decomposition in aqueous solution, and effectively increase plasma circulation time.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17012972
- 003
- CZ-PrNML
- 005
- 20170517081921.0
- 007
- ta
- 008
- 170413s2016 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2016.013 $2 doi
- 035 __
- $a (PubMed)27003313
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hrubý, Martin, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1978 prosinec 15.- $7 xx0060770
- 245 10
- $a Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs / $c M. Hruby, K. Agrawal, O. Policianova, J. Brus, J. Skopal, P. Svec, M. Otmar, P. Dzubak, P. Stepanek, M. Hajduch
- 520 9_
- $a BACKGROUND: The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs is confounded by their hydrolytic lability which decreases plasma circulation time. Here, we describe a new biodegradable, polyanhydride formulation for drug delivery that circumvents this drawback. METHODS: Injectable/implantable polymeric microbeads containing dispersed microcrystals of hydrophilic AZA or DAC packed in a dry environment are protected from hydrolysis, until the hydrolytic zone reaches the core. Diclofenac is embedded into the formulation to decrease any local inflammation. The efficacy of the formulations was confirmed by monitoring the induced demethylation, and cytostatic/cytotoxic effects of continuous drug release from the time-course dissolution of the microbeads, using an in vitro developed cell based reporter system. RESULTS: Poly(sebaccic acid-co-1,4-cyclohexanedicarboxylic acid) containing 30 wt. % drug showed zero-order release (R(2) = 0.984 for linear regression), and release rate of 10.0 %/h within the first 5 h, and subsequent slower release of the remaining drug, thus maintaining the level of drugs in the outer environment considerably longer than the typical plasma half-life of free azanucleosides. At lower concentrations, the differences between powder drug formulations and microbeads were very low or negligible, however, at higher concentrations, we discovered equivalent or increasing effects of the drugs loaded in microbeads. CONCLUSIONS: The study provides evidence that microbead formulations of the hydrolytically labile azanucleoside drugs could prevent their chemical decomposition in aqueous solution, and effectively increase plasma circulation time.
- 650 _2
- $a vstřebatelné implantáty $7 D020341
- 650 _2
- $a protinádorové antimetabolity $x aplikace a dávkování $x farmakologie $7 D000964
- 650 _2
- $a azacytidin $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D001374
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a implantabilní infuzní pumpy $7 D015918
- 650 _2
- $a magnetická rezonanční spektroskopie $7 D009682
- 650 _2
- $a mikrosféry $7 D008863
- 650 _2
- $a polymery $x chemie $7 D011108
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Agrawal, Kushboo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 _AN073524
- 700 1_
- $a Policianova, Olivia $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
- 700 1_
- $a Brus, Jiří, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1970- $7 jo2011640489
- 700 1_
- $a Skopal, Jan $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic
- 700 1_
- $a Švec, Pavel $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $7 _AN089436
- 700 1_
- $a Otmar, Miroslav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $7 xx0121125
- 700 1_
- $a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0080445
- 700 1_
- $a Štěpánek, Petr, $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic $d 1952- $7 xx0027070
- 700 1_
- $a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0050218
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 2 (2016), s. 222-230
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170425143042 $b ABA008
- 999 __
- $a ok $b bmc $g 1205368 $s 973745
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 160 $c 2 $d 222-230 $e 20160321 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170413